RAB30

Across TCGA pan-cancer cohorts, RAB30 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB30 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAB30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB30 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BRCA, and UCEC are the cancer types where RAB30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.158	0.712	<.001	27	view →
BRCA	OS	Median	III,IV	0.233	0.833	.001	20	view →
UCEC	DFS	Median	All	1.000	0.891	.020	16	view →
BLCA	OS	Median	III,IV	0.117	0.684	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB30–LUAD (OS)

Open the LUAD breakdown →